President Bush Names Niederhuber NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

WASHINGTON—President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

Dr. Niederhuber brings a wealth of experience to NCI, as a former cancer center director, former chair of the National Cancer Advisory Board (NCAB), member of the Institute's senior management team for the last year, and acting NCI director since June 2006. In addition to his NCI administrative duties, Dr. Niederhuber holds a clinical appointment as a member of the medical staff at the NIH Clinical Centers.

Dr. Niederhuber joined NCI in September 2005 as deputy director for translational and clinical sciences and almost immediately became NCI's chief operating officer after Dr. von Eschenbach was named FDA acting director.

Dr. Niederhuber came to NCI from the University of Wisconsin School of Medicine, where he served as professor of surgery and oncology and as director of its Comprehensive Cancer Center from 1997 to 2002. Dr. Niederhuber earned his medical degree at Ohio State University School of Medicine, Columbus.

Related Videos
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content